US contractor upholds Pacific Edge's Medicare ban

US contractor upholds Pacific Edge's Medicare ban
Pacific Edge has had a fresh blow to its hopes for access to the US Medicare market for Cxbladder diagnostic tests. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge’s flagship Cxbladder cancer testing has been deemed as “not considered medically reasonable and necessary” by the company’s United States Medicare administrator. The statement is in a new proposed Local Coverage Determination (LCD) for Medicare and is a fresh blow for the company’s hopes to quickly regain long-term access to the Medicare system for its bladder cancer tests.Medicare is Pacific Edge’s largest customer.The new LCD was released overnight New Zealand time by Novitas, Pacific Edge...

More Markets

82 staff leave Meridian after retail 'reset'
Markets

82 staff leave Meridian after retail 'reset'

Expect a very different approach from Meridian in 2025, executive says.

NZX, NZSA want level playing field in climate reporting
Markets

NZX, NZSA want level playing field in climate reporting

Climate reporting liabilities for company directors could soon be eased.

Cannasouth delisting keeps Petterson in charge
Markets

Cannasouth delisting keeps Petterson in charge

Cannasouth major shareholders pushed to end voluntary administration they had called in.

Garth Bray 10:30am
Chorus' four-year revenue cap set at $4.1b
Markets

Chorus' four-year revenue cap set at $4.1b

ComCom says it has saved consumers $172.6m over the past four years.